|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inhibition of mutated, activated BRAF in metastatic melanoma 显示文摘 | Flaherty KT Puzanov I Kim KB | 2010 | N Engl J Med2010，363，9： | 1 |
| 2 | The MAPK pathway in melanoma显示文摘 | Fecher LA Amaravadi RK Flaherty KT | | 0，，02： | 1 |
| 3 | Hyperspectral ima- ging= a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor显示文摘 | Dicker DT Kahn N Flaherty KT | 2011 | Cancer BiolTher2011，12，4： | 1 |
| 4 | Improved survival with MEK inhibition in BRAF-mntated melanoma显示文摘 | Flaherty KT Robert C Hersey P | 2012 | N Engl J Med2012，367，2： | 1 |
| 5 | Clinical activity and immune modulation in cancer patients treat- ed with CP-870, 893, a novel CD40 agonist monoclonal antibody显示文摘 | Vonderheide RH Flaherty KT Khalil M | 2007 | J Clin Oncol2007，25，7： | 1 |
| 6 | Phase Ⅰ/Ⅱ trial of BAY 43-9006, carboplatin (C) and paelitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma (abst) 显示文摘 | Flaherty KT Brose M Sehuehter L | 2004 | Proc Am Soc Clin Oncol2004，22，： | 1 |
| 7 | The MAPK pathway inmelanoma显示文摘 | Fecher LA Amaravadi RK Flaherty KT | 2008 | Curr Opin Oncol2008，20，： | 1 |
| 8 | Phase II ,open- label,single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kitmutation or amplifica- t ion显示文摘 | Guo J Si L Kong Y Flaherty KT | 2011 | J Clin Oneol2011，29，21： | 1 |
| 9 | Final results of E2603: a double-blind, randomized phase Ⅲ trial com- paring carboplatin (C)/paclitaxel (P) with or without so- rafenib (S) in metastatic melanoma显示文摘 | Flaherty KT Lee S J Schuchter LM | 2010 | J Clin Oncol2010，28，15： | 1 |
| 10 | A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil leucovorin andirinotecan显示文摘 | Midgley RS Kerr D J Flaherty KT | 2007 | Ann Oncol2007，18，12： | 1 |
| 11 | A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States)显示文摘 | Flaherty KT Fuchs CS Colditz GA | 2005 | Cancer Causes Control2005，16，9： | 1 |
| 12 | Improved survival with MEK inhibition in BRAF-mutated melanoma显示文摘 | Flaherty KT Robert C Hersey P | 2012 | N En- gl J Med2012，367，2： | 1 |
| 13 | Mechanisms of hypertension associated with BAY 43-9006显示文摘 | VeroneseML Mosenkis A Flaherty KT | 2006 | J Clin Oncol2006，22，： | 1 |
| 14 | Sorafenib in adcanced melanoma: a phase Ⅱ randomized discontinuation trial analysis 显示文摘 | Eisen T Ahmad T Flaherty KT | 2006 | Br J Cancer2006，95，： | 1 |
| 15 | Interaction of sorafenib andcytochrome P450 isoenzymes in patients with advanced melanoma : aphase I/II pharmacokinetic interaction study显示文摘 | Flaherty KT Lathia C Frye RF | 2011 | Cancer ChemotherPharmacol2011，68，： | 1 |
| 16 | Sorafenib in advanced melanoma: a Phase Ⅱ randomised discontinuation trial analysis显示文摘 | Eisen T Ahmad T Flaherty KT | 2006 | Br J Cancer2006，95，5： | 1 |
| 17 | Sorafenib in advanced melanoma: a phase Ⅱ randomised discontinuation trial analysis 显示文摘 | Eisen T Ahmad T Flaherty KT | 2006 | Br J Cancer2006，95，5： | 1 |
| 18 | Sorafenib in advanced melanoma: a phase Ⅱ randomised discontinuation trial analysis显示文摘 | Eisen T Abroad T Flaherty KT | 2006 | Br J Cancer2006，95，5： | 1 |
| 19 | Sorafenib in advanced melanoma: a phase 11 randomised discontinuation trial analysis显示文摘 | Eisen T Ahmad T Flaherty KT | 2006 | Br J Cancer2006，95，5： | 1 |
| 20 | Phase Ⅰ/Ⅱ trial of BAY43-9006, carboplatin(C)and paclitax(P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma (abstract)显示文摘 | Flaherty KT Brose M Schuchter L | 2004 | Proc Am Soc Clin Oncol2004，22，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员